Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2015. The document serves as a notification of transactions involving a Person Discharging Managerial Responsibilities (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific executive compensation event.
Material Changes
The filing details a change in the interests of Mrs. V A Whyte following the vesting of 25% of an award made on July 8, 2010, under the GlaxoSmithKline Deferred Investment Award Plan. The transaction involves 3,673.639 notional Ordinary shares, with a cash payment of 1,347.50 pence per share scheduled for August 20, 2015.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a regulatory disclosure required under paragraph 3.1.4R(1)(a) of the Disclosure and Transparency Rules.
Investor Verification Points
- Verify the vesting schedule and terms of the GlaxoSmithKline Deferred Investment Award Plan.
- Confirm the total cash payout amount for Mrs. V A Whyte based on the share count and price per share.
- Note that this filing does not reflect the company's overall financial performance for the period.